SCHEMBL4864697

SCHEMBL4864697

OCCOCCNc1nc(-c2ccccc2)nc2ccccc12

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.73
PDE5A O76074 3/20 0.68
LATS1 O95835 1/20 0.67
KDM4E B2RXH2 5/20 0.66
RECQL P46063 2/20 0.66
GBA1 P04062 6/20 0.62
MEN1 O00255 4/20 0.62
KMT2A Q03164 4/20 0.62
MAPT P10636 4/20 0.62
ALDH1A1 P00352 4/20 0.62
SMN1; SMN2 Q16637 1/20 0.62
SIRT5 Q9NXA8 1/20 0.61
LMNA P02545 3/20 0.61
PKM P14618 2/20 0.61
POLB P06746 1/20 0.61
HPGD P15428 2/20 0.60
ACP1 P24666 1/20 0.60
GAA P10253 1/20 0.57
TP53 P04637 1/20 0.57
CYP1A2 P05177 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7606647 0.93 LATS1 (0.79) MAPK1PDE5ALATS1KDM4ERECQL
SCHEMBL4868364 0.92 MEN1 (0.74) MAPK1PDE5ALATS1KDM4ERECQL
SCHEMBL7606516 0.87 LATS1 (0.58) MAPK1PDE5ALATS1KDM4ERECQL
SCHEMBL7633218 0.85 ALDH1A1 (0.56) MAPK1PDE5ALATS1KDM4ERECQL
SCHEMBL7607086 0.85 MEN1 (0.56) MAPK1PDE5ALATS1KDM4ERECQL
SCHEMBL7612782 0.85 LATS1 (0.56) MAPK1PDE5ALATS1KDM4ERECQL
SCHEMBL7610714 0.84 METAP1 (0.67) MAPK1PDE5ALATS1KDM4EGBA1
SCHEMBL7609194 0.83 KDM1A (0.55) MAPK1PDE5ALATS1KDM4ERECQL
SCHEMBL7610940 0.83 GBA1 (0.78) MAPK1PDE5ALATS1KDM4EGBA1
SCHEMBL7611453 0.83 PDE5A (0.62) MAPK1PDE5ALATS1KDM4ERECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US claimed
JP-2008526734-A 2008-07-24 JP claimed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP claimed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO claimed
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US disclosed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP disclosed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY GPR119, GCKR, GLP1R MAPK1 513/4885PDE5A 204/4885LATS1 4035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.